854 related articles for article (PubMed ID: 26976701)
1. High Variation of Intravitreal Injection Rates and Medicare Anti-Vascular Endothelial Growth Factor Payments per Injection in the United States.
Erie JC; Barkmeier AJ; Hodge DO; Mahr MA
Ophthalmology; 2016 Jun; 123(6):1257-62. PubMed ID: 26976701
[TBL] [Abstract][Full Text] [Related]
2. Estimating Medicare and Patient Savings From the Use of Bevacizumab for the Treatment of Exudative Age-related Macular Degeneration.
Rosenfeld PJ; Windsor MA; Feuer WJ; Sun SJJ; Frick KD; Swanson EA; Huang D
Am J Ophthalmol; 2018 Jul; 191():135-139. PubMed ID: 29655642
[TBL] [Abstract][Full Text] [Related]
3. Joint Management of Cataract Surgery by Ophthalmologists and Optometrists.
Erie JC; Hodge DO; Mahr MA
Ophthalmology; 2016 Mar; 123(3):505-13. PubMed ID: 26681394
[TBL] [Abstract][Full Text] [Related]
4. Estimating Public and Patient Savings From Basic Research-A Study of Optical Coherence Tomography in Managing Antiangiogenic Therapy.
Windsor MA; Sun SJJ; Frick KD; Swanson EA; Rosenfeld PJ; Huang D
Am J Ophthalmol; 2018 Jan; 185():115-122. PubMed ID: 29224686
[TBL] [Abstract][Full Text] [Related]
5. Experience of New Brunswick ophthalmologists using intravitreal anti-vascular endothelial growth factor.
Giberson M; Taylor V
Can J Ophthalmol; 2015 Oct; 50(5):393-4. PubMed ID: 26455977
[No Abstract] [Full Text] [Related]
6. Intravitreal Anti-Vascular Endothelial Growth Factor Cost Savings Achievable with Increased Bevacizumab Reimbursement and Use.
Glasser DB; Parikh R; Lum F; Williams GA
Ophthalmology; 2020 Dec; 127(12):1688-1692. PubMed ID: 32544559
[TBL] [Abstract][Full Text] [Related]
7. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.
Parikh R; Ross JS; Sangaralingham LR; Adelman RA; Shah ND; Barkmeier AJ
Ophthalmology; 2017 Mar; 124(3):352-358. PubMed ID: 27890437
[TBL] [Abstract][Full Text] [Related]
8. Variation in Ophthalmologist Use of Antivascular Endothelial Growth Factor Therapy Among Medicare Beneficiaries.
Thakore RV; Greenberg PB; Behrens JJ; French DD
JAMA Ophthalmol; 2016 Sep; 134(9):1071-2. PubMed ID: 27366859
[No Abstract] [Full Text] [Related]
9. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
Brown GC; Brown MM; Rapuano S; Boyer D
Am J Ophthalmol; 2020 Oct; 218():225-241. PubMed ID: 32565050
[TBL] [Abstract][Full Text] [Related]
10. Physician-Industry Interactions and Anti-Vascular Endothelial Growth Factor Use Among US Ophthalmologists.
Taylor SC; Huecker JB; Gordon MO; Vollman DE; Apte RS
JAMA Ophthalmol; 2016 Aug; 134(8):897-903. PubMed ID: 27356110
[TBL] [Abstract][Full Text] [Related]
11. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file.
Brechner RJ; Rosenfeld PJ; Babish JD; Caplan S
Am J Ophthalmol; 2011 May; 151(5):887-895.e1. PubMed ID: 21310390
[TBL] [Abstract][Full Text] [Related]
12. Association between Industry Payments and Anti-vascular Endothelial Growth Factor Use in Medicare Beneficiaries.
Mahr MA; Hodge DO; Erie JC
Ophthalmol Retina; 2017; 1(1):19-24. PubMed ID: 31047391
[TBL] [Abstract][Full Text] [Related]
13. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.
Souied EH; Dugel PU; Ferreira A; Hashmonay R; Lu J; Kelly SP
Ophthalmic Epidemiol; 2016; 23(2):71-9. PubMed ID: 26855278
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
[TBL] [Abstract][Full Text] [Related]
15. Endophthalmitis Rates after Bilateral Same-Day Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
Borkar DS; Obeid A; Su DC; Storey PP; Gao X; Regillo CD; Kaiser RS; Garg SJ; Hsu J;
Am J Ophthalmol; 2018 Oct; 194():1-6. PubMed ID: 29981738
[TBL] [Abstract][Full Text] [Related]
16. Physician Utilization Patterns for VEGF-Inhibitor Drugs in the 2012 United States Medicare Population: Bevacizumab, Ranibizumab, and Aflibercept.
Baisiwala S; Bundorf MK; Pershing S
Ophthalmic Surg Lasers Imaging Retina; 2016 Jun; 47(6):555-62. PubMed ID: 27327285
[TBL] [Abstract][Full Text] [Related]
17. The Biosimilar Paradox: How Anti-Vascular Endothelial Growth Factor Biosimilars Could Increase Patient and Overall Health Care Costs.
Zhang C; Friedman S; Mruthyunjaya P; Parikh R
Ophthalmology; 2023 Sep; 130(9):966-972. PubMed ID: 37116720
[TBL] [Abstract][Full Text] [Related]
18. A longitudinal study to assess the frequency and cost of antivascular endothelial therapy, and inequalities in access, in England between 2005 and 2015.
Hollingworth W; Jones T; Reeves BC; Peto T
BMJ Open; 2017 Oct; 7(10):e018289. PubMed ID: 29061629
[TBL] [Abstract][Full Text] [Related]
19. The Relationship between Medicare Payment and Service Volume for Retina Procedures from 2005 through 2009.
Gong D; Jun L; Tsai JC
Ophthalmology; 2015 Aug; 122(8):1609-14. PubMed ID: 26050540
[TBL] [Abstract][Full Text] [Related]
20. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]